TY  - GEN
AU  - Roussel,Murielle
AU  - Moreau,Philippe
AU  - Huynh,Anne
AU  - Mary,Jean-Yves
AU  - Danho,Clotaire
AU  - Caillot,Denis
AU  - Hulin,Cyrille
AU  - Fruchart,Christophe
AU  - Marit,Gérald
AU  - Pégourié,Brigitte
AU  - Lenain,Pascal
AU  - Araujo,Carla
AU  - Kolb,Brigitte
AU  - Randriamalala,Edouard
AU  - Royer,Bruno
AU  - Stoppa,Anne-Marie
AU  - Dib,Mammoun
AU  - Dorvaux,Véronique
AU  - Garderet,Laurent
AU  - Mathiot,Claire
AU  - Avet-Loiseau,Hervé
AU  - Harousseau,Jean-Luc
AU  - Attal,Michel
TI  - Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
SN  - 1528-0020
PY  - 2010///0121
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Boronic Acids
KW  - adverse effects
KW  - Bortezomib
KW  - Case-Control Studies
KW  - Demography
KW  - Disease Progression
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - France
KW  - Humans
KW  - Male
KW  - Melphalan
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Pyrazines
KW  - Stem Cell Transplantation
KW  - Survival Analysis
KW  - Transplantation Conditioning
KW  - Transplantation, Autologous
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2009-06-229658
ER  -